Sight Sciences, Inc. SGHT
Our mission is to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing. We are passionate about improving patients' lives by helping them to preserve their sight. Our business philosophy is grounded in the following principles: comprehensively understanding disease physiology; developing transformative technologies that are intended to preserve, protect, and restore natural physiological functionality to diseased eyes; developing and marketing products with proven clinical evidence that achieve superior effectiveness versus current treatment paradigms while minimizing complications or side effects; providing intuitive, patient-friendly, interventional solutions to eye care professionals ("ECPs"); and delivering compelling economic value to all stakeholders, including patients, providers and third-party payors such as Medicare and commercial insurers. Our objective is to develop and market products for use in new treatment paradigms and to create an interventional mindset in eyecare whereby our technologies may be used in procedures which supplant conventional outdated approaches.
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by segment
- Interventional Glaucoma
- Interventional Dry Eye
| Segment | FY2025 | FY2024 |
|---|---|---|
| Interventional Glaucoma | $75.7M | $75.9M |
| Interventional Dry Eye | $1.6M | $4.0M |
As the company reported it, from the “Segment Information - Summary of Operating Result Information for Each Reportable Segment (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $77.4M | $79.9M | $81.1M | $71.3M | $49.0M | $27.6M | — |
| Cost of revenue | $10.7M | $11.6M | $11.9M | $12.4M | $8.6M | $9.2M | — |
| Gross profit | $66.7M | $68.3M | $69.2M | $59.0M | $40.3M | $18.4M | — |
| R&D | $14.6M | $18.0M | $17.6M | $22.9M | $15.6M | $8.9M | — |
| SG&A | $89.2M | $100.8M | $108.9M | $120.1M | $76.2M | $41.7M | — |
| Total operating expenses | $103.8M | $118.8M | $126.4M | $142.9M | $91.8M | $50.6M | — |
| Operating income | -$37.1M | -$50.5M | -$57.3M | -$84.0M | -$51.5M | -$32.2M | — |
| Interest expense | $5.1M | $4.7M | $5.4M | $4.5M | $4.4M | $2.4M | — |
| Pre-tax income | -$38.4M | -$51.3M | -$55.4M | -$86.2M | -$62.8M | -$34.6M | — |
| Income tax | $10.0K | $236.0K | $110.0K | $47.0K | $188.0K | $61.0K | — |
| Net income | -$38.4M | -$51.5M | -$55.5M | -$86.2M | -$63.0M | -$34.7M | — |
| EPS, basic | -0.74 | -1.03 | -1.14 | -1.80 | -2.36 | — | — |
| EPS, diluted | -0.74 | -1.03 | -1.14 | -1.80 | -2.36 | -3.71 | — |
| Shares, diluted (wtd. avg.) | 52.1M | 50.1M | 48.6M | 47.8M | 26.7M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $92.0M | $120.4M | $138.1M | $185.0M | $260.7M | $61.5M | $21.2M |
| Receivables | $9.7M | $10.8M | $14.3M | $15.1M | $8.7M | $5.4M | — |
| Inventory | $7.8M | $6.3M | $7.8M | $6.1M | $3.5M | $2.6M | — |
| Total current assets | $112.7M | $139.8M | $162.9M | $209.7M | $277.0M | $70.6M | — |
| Property, plant and equipment | $1.6M | $1.6M | $1.6M | $1.6M | $1.5M | $1.3M | — |
| Total assets | $115.3M | $142.8M | $166.7M | $213.1M | $280.2M | $72.8M | — |
| Accounts payable | $1.3M | $1.7M | $1.7M | $2.7M | $3.4M | $2.2M | — |
| Short-term debt | $0 | $0 | $2.2M | $0 | $0 | $0 | — |
| Total current liabilities | $11.0M | $15.5M | $12.3M | $17.8M | $13.5M | $9.3M | — |
| Long-term debt | $40.3M | $39.4M | $31.7M | $33.3M | $32.7M | $32.0M | — |
| Total liabilities | $51.4M | $55.3M | $46.4M | $53.0M | $48.1M | $44.3M | — |
| Retained earnings | -$384.7M | -$346.3M | -$294.8M | -$239.2M | -$153.0M | -$90.0M | — |
| Total equity | $63.9M | $87.5M | $120.2M | $160.1M | $232.1M | -$88.8M | -$54.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$29.7M | -$22.4M | -$47.2M | -$76.0M | -$52.5M | -$32.2M | — |
| Depreciation and amortisation | $487.0K | $712.0K | $614.0K | $710.0K | $632.0K | $554.0K | — |
| Stock-based compensation | $13.1M | $17.1M | $14.6M | $13.0M | $5.1M | $497.0K | — |
| Capital expenditure | $224.0K | $385.0K | $791.0K | $970.0K | $813.0K | $953.0K | — |
| Investing cash flow | -$224.0K | -$385.0K | -$791.0K | -$970.0K | -$813.0K | -$953.0K | — |
| Financing cash flow | $1.8M | $5.0M | $1.1M | $1.2M | $252.5M | $73.4M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-091558.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $27.6M | $49.0M | $71.3M | $81.1M | $79.9M | $77.4M |
| Gross profit | — | $18.4M | $40.3M | $59.0M | $69.2M | $68.3M | $66.7M |
| Net income | — | -$34.7M | -$63.0M | -$86.2M | -$55.5M | -$51.5M | -$38.4M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |